Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T00:42:19.521Z Has data issue: false hasContentIssue false
  • English
  • Français

Ofloxacin

Published online by Cambridge University Press:  21 June 2016

Allan R. Tunkel  and
W. Michael Scheld
Allan R. Tunkel*
Affiliation:
Department of Internal Medicine (Infectious Diseases), Medical College of Pennsylvania, Philadelphia, Pennsylvania
W. Michael Scheld
Affiliation:
Departments of Internal Medicine (Infectious Diseases) and Neurosurgery, The University of Virginia Health Sciences Center, Charlottesville, Virginia
*
Division of Infectious Diseases, Medical College of Pennsylvania, 3300 Henry Ave., Philadelphia, PA 19129
Get access Rights & Permissions [Opens in a new window]

Extract

The fluoroquinolone antibiotic agents have been a major advance in the treatment of bacterial infections. The original quinolone nalidixic acid suffered from a narrow spectrum of activity and rapid development of drug resistance. The newer fluoroquinolones have more desirable properties including good oral absorption, enhanced antimicrobial activity, improved pharmacokinetic profile, and limited adverse effects. These improvements are the results of two structural modifications: addition of a fluorine atom at position 6; and addition of a piperazyl moiety at position 7 of the bicyclic nucleus. The three fluoroquinolones currently available in the United States are norfloxacin, ciprofloxacin, and ofloxacin. This review focuses on ofloxacin, the newly licensed agent, emphasizing the salient features of the drug and specific indications for use.

Type
Clinical Pharmacology of Antibiotics
Information
Infection Control & Hospital Epidemiology , Volume 12 , Issue 9 , September 1991 , pp. 549 - 557
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1991

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Wolfson, JS, Hooper, DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989;2:378–424.Google Scholar
2. Hooper, DC, Wolfson, JS. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991;324:384–394.Google Scholar
3. Neu, HC. Chemical evolution of the fluoroquinolone antimicrobial agents. Am J Med. 1989;87:2S–9S.Google Scholar
4. Hayakawa, I, Atarashi, S, Yokohama, S, Imamura, M, Sakano, KI, Furukawa, M. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother. 1986;29:163–164.Google Scholar
5. Neu, HC, Chin, NX. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother. 1989;33:1105–1107.Google Scholar
6. Gellert, M. DNA topoisomerases. Annu Rev Biochem. 1981;50 879–910.CrossRefGoogle ScholarPubMed
7. Fernandes, PB. Mode of action, and in vitro and in vivo activities of the fluoroouinolones. J Clin Pharmacol. 1988;28:156–168.Google Scholar
8. Hooper, DC,’ Wolfson, JS. Mode of action of the quinolone antimicrobial agents: review of recent information. Rev Infect Dis. 1989;11(supp1 5):S902–S911.Google Scholar
9. Wolfson, JS, Hooper, DC. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis. 1989;11 (suppl 5):S960–S968.Google Scholar
10. Hooper, DC, Wolfson, JS. Bacterial resistance to the quinolone antimicrobial agents. Am J Med. 1989;87:17S–23S.Google Scholar
11. Monk, JP, Campoli-Richards, DM. Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1987;33:346–391.CrossRefGoogle ScholarPubMed
12. Fuchs, PC. In vitro antimicrobial activity and susceptibility testing of ofloxacin. Current status. Am J Med. 1989;87:10S-13S.Google Scholar
13. McEwen, A. Roberts, G. In vitro activity of ofloxacin against isolates of Neisseria gonorrhoeae. J Antimicrob Chemother. 1988;22(suppl C)21–25.Google Scholar
14. Kumada, T, Neu, HC. In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents. J Antimicrob Chemother. 1985;16:563–574.Google Scholar
15. Gruneberg, RN, Felmingham, D, O'Hare, MD, et al. The comparative in vitro activity of ofloxacin. J Antimicrob Chemother. 1988;22 (suppl C)9–19.Google Scholar
16. Saito, A, Sawatari, K, Fukuda, Y, et al. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea Digs. Antimicrob Agents Chemother. 1985;28:15–20.Google Scholar
17. Osada, Y, Ogawa, H. Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother. 1983;23:509–511.Google Scholar
18. Tsukamura, M. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL 8280). Am Rev Resp Dis. 1985;131:348–351.Google Scholar
19. Fenlon, CH, Cynamon, MH. Comparative in vitro activity of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulars . Antimicrob Agents Chemother. 1986;29:386–388.Google Scholar
20. Schacter, J, Moncada, JV. In vitro activity of ofloxacin against Chlamvdia trachomatis . Am J Med. 1989;87:14S–16S.Google Scholar
21. Lode, H, Hoffken, G, Olschkwski, P, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987;31 1338–1342.Google Scholar
22. Wise, R, Lockley, MR. The pharmacokinetics of ofloxacin and review of its tissue penetration. J Antimicrob Chemother. 1988;22 (suppl C)59–64.CrossRefGoogle ScholarPubMed
23. Flor, S. Pharmacokinetics of ofloxacin. An overview. Am J Med. 1989;87:24S–30S.Google Scholar
24. Kalager, T, Digranes, A, Bergan, T, Rolstad, T. Ofloxacin: serum and skin blister pharmacokinetics in the fasting and non-fasting state. J Antimicrob Chemother. 1986;17:795–800.Google Scholar
25. Leroy, A, Borsa, F, Humberg, G, Bernadet, P, Fillastre, JP. The pharmacokinetics of ofloxacin in healthy adult male volunteers. Eur J Clin Pharmacol. 1987;31:629–630.CrossRefGoogle ScholarPubMed
26. Maesen, FPV, Davies, BI, Geraedts, WH, Sumajow, CA. Ofloxacin and antacids. J Antimicrob Chemother. 1987;19:848–850.CrossRefGoogle ScholarPubMed
27. Hoffken, G, Lode, H, Wiley, R, et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect on food and antacid intake. Rev Infect Dis. 1988;10(suppl 1):S138–S139.Google Scholar
28. Stille, W, Harder, S, Mieke, S, et al. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother. 1987:20:729–734.Google Scholar
29. Wijnands, GJA, Vree, TB, Janssen, TJ, Guelen, PJM. Drug-drug interactions affecting fluoroquinolones. Am /Med. 1989;87:47S–51s.Google Scholar
30. Leor, J, Matetzki, S. Ofloxacin and warfarin. Ann Intern Med. 1988;109:761.Google Scholar
31. Wolfson, JS, Hooper, DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med. 1989;87:31S–36S.Google Scholar
32. Fillastre, JP, Leroy, A, Humbert, G. Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother. 1987;31:156–160.CrossRefGoogle ScholarPubMed
33. Graber, H, Ludwig, E, Arr, M, Lanyl, P. Pharmacokinetics of ofloxacin in young and elderly patients. Rev Infect Dis. 1988;10(suppl 1):S106.Google Scholar
34. Norrby, SR, Ljungberg, B. Pharmocokinetics of fluorinated 4-quinolones in the aged. Rev Infect Dis. 1989;11(suppl 5):S1102–S1106.CrossRefGoogle Scholar
35. White, LO, MacGowan, AP, Mackay, IG, Reeves, DS. The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal disease. J Antimicrob Ckemothel: 1988;22(suppl C)65–72.Google Scholar
36. Chan, MK, Chau, PY, Chan, WWN. Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol. 1987;28:277–280.Google Scholar
37. Wise, R, Lockley, MR. The pharmacokinetics of ofloxacin and a review of its tissue penetration. J Antimicrob Ckemothel: 1988;22 (suppl C)59–64.Google Scholar
38. Warlich, R, Korting, HC, Schafer-Korting, M, Mutschler, E. Multiple-dose pharmacokiietics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers. Antimicrob Agents Ckemothel: 1990;34:78–81.Google Scholar
39. Navarro, AS, Lanao, JM, Sanchez Recio, MM, et al. Effect of renal impairment on distribution of ofloxacin. Antimicrob Agents Ckemotker: 1990;34:455–459.Google Scholar
40. Bitar, N, Claes, R, Van der Auwera, P. Concentration of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally. Antimicrob Agents Chemother. 1989;33:1686–1690.Google Scholar
41. Stahl, JP, Croize, J, Lefebvre, MA, et al. Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis. Infection. 1986:14(suppl 4):S254–S255.Google Scholar
42. Stubner, RG, Weinrich, W, Brands, U. Study of the cerebrospinal fluid penetrability of ofloxacin. Infection. 1986;14 (suppl 4):S250–S253.Google Scholar
43. Pioget, JC, Wolff, M, Singlas, E, et al. Diffusion of ofloxacin into cerebrospinal fluid of patients with purulent meningitis or ventriculitis. Antimicrob Agents Chemother. 1989;33:933–936.Google Scholar
44. Blomer, P, Bruch, K. Zohlten, RN. A summary of clinical nhase II and phase III study results on ofloxacin (HOE 280) in Europe. Infection. 1986;14(suppl 1):S102–S107.Google Scholar
45. Kromann-Andersen, B, Nielsen, KK. Ofloxacin and urinary tract infections. Scand J Infect Dis Suppl. 1990;68:35–40.Google ScholarPubMed
46. Ode, B, Walder, M, Forsgren, A. Failure of a single dose of 100 mg ofloxacin in lower urinary tract infection in females. Scand J Infect Dis. 1987;19:677–679.Google Scholar
47. Ludwig, G, Pauthner, H. Clinical experience with ofloxacin in upper and lower urinary tract infections. A comparison with co-trimoxazole and nitrofurantoin. Drugs. 1987;34(suppl 1)95–99.CrossRefGoogle ScholarPubMed
48. Block, JM, Walstad, RA, Bjertnaes, A, et al. ofloxacin versus trimethoprim-sulfamethoxazole in acute cystitis. Drugs. 1987;34(suppl l)100–106.Google Scholar
49. Hooton, TM, Latham, RH, Wong, ES, Johnson, C, Roberts, PL, Stamm, WE. ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis. Antimicrob Agents Ckemothel: 1989;33:1308–1312.Google Scholar
50. Hooton, TM, Johnson, C, Winter, C, et al. Single-dose and three-day regimens of ofloxacin versus trimethoprim- sulfamethoxazole for acute cystitis in women. Antimicrob Agents Chemother. 1991;35:1479–1483.CrossRefGoogle ScholarPubMed
51. Kishi, H, Nito, H, Saito, L, Nishimura, Y, Niijima, T. Comparative studies of DL-8280 and pipemidic acid in complicated urinary tract infections by double-blind method. Acta Urol Jpn. 1984;30:1307–1355.Google Scholar
52. Vogt, P, Schorn, T, Frei, U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection. 1988$X75–178.Google Scholar
53. Kromann-Andersen, B, Sommer, P, Pers, C, Larsen, V, Rasmussen, F. Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections. J Antimicrob Chemother 1988;22(suppl C)143–147.Google Scholar
54. Cox, CE. Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Am J Med. 1989;87:61S-68S.Google Scholar
55. Remy, G, Rouger, C, Chavanet, P, Bernard, E, Dellamonica, P, Portier, H. Use of ofloxacin for prostatitis. Rev Infect Dis. 1988;10 (suppl 1):S173–S174.Google Scholar
56. Black, JR, Long, JM, Zwickl, BE, et al. Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection. Antimicrob Agents Chemother 1989;33:167–170.Google Scholar
57. Lutz, FB Jr. Single-dose efficacy of ofloxacin in uncomplicated gonorrhea. Am J Med. 1989;87:69S-74S.Google ScholarPubMed
58. Ariyarit, C, Panikabutra, K, Chitwarakorn, A, Wongba, C, Buatiang, A. Efficacy of ofloxacin in uncomplicated gonorrhea. Infection. 1986;14(supp1 4):S311–S313.CrossRefGoogle Scholar
59. Covino, JM, Cummings, M, Smith, B, Benes, S, Draft, K, McCormack, WM. Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains. Antimicrob Agents Chemother. 1990;34:148–149.Google Scholar
60. Hooper, DC, Wolfson, JS. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrob Agents Chemother. 1989;33:1662–1667.Google Scholar
61. Oriel, JD. Use of quinolones in chlamydial infection. Rev Infect Dis. 1989; 11 (supp1 5):S1273–S1276.Google Scholar
62. Fransen, L, Avonts, D. Piot RTreatment of genital chlamydial infection with ofloxacin. Infection. 1986;14(supp1 4):S318–S320.Google Scholar
63. Batteiger, BE, Jones, RB, White, A. Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease. Am J Med. 1989;87:75S-77S.Google Scholar
64. Mogabgab, WJ, Holmes, B, Murray, M, Beville, R, Lutz, FB, Tack, KJ. Randomized comparison of ofloxacin and doxycycliie for Chlamydia and Ureaplasma urethritis and cervicitis. Chemotherapy. 1990;36:70–76.CrossRefGoogle ScholarPubMed
65. Moller, BR, Hermann, B, Ibsen, HHW, Halkier Sorensen, L, From, E, Mardh, PA. Occurrence of Ureaplasma urealyticus and Mycoplasma hominis in non-gonococcal urethritis before and after treatment in a double-blind trial of ofloxacin versus erythromycin. Scand J Infect Dis Suppl. 1990;68:31–34.Google Scholar
66. Ball, P. Overview of experience with ofloxacin in respiratory tract infections. Scand J Infect Dis Suppl. 1990;68:56–63.Google Scholar
67. Egede, F, Kristensen, I. A clinical comparative study of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1988;22 (suppl C)139–142.Google Scholar
68. Stocks, JM, Wallace, RJ Jr, Griffith, DE, Garcia, JG, Kohler, RB. ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. Am J Med. 1989;87:52S-56S.Google Scholar
69. Jensen, T, Pedersen, SS, Nielsen, CH, Hoiby, N, Koch, C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Ckemothel: 1987;20:585–594.Google Scholar
70. Meek, JCE, Maesen, FPV, Davies, BI. A prospective study of ofloxacin in acute exacerbations of chronic respiratory disease associated with Pseudomonas aeruginosa . J Antimicrob Chemother. 1989;24:447–453.Google Scholar
71. Grassi, GG. A multi-center study, on clinical efficacy of ofloxacin in respiratory and urinary tract infections. Infection. 1986;14(suppl 4):S300–S302.Google Scholar
72. Kobayashi, H. Clinical evaluation of ofloxacin in lower respiratory tract infections. Infection. 1986;14(supp1 4):S279–S282.Google Scholar
73. Lipsky, BA, Tack, KJ, Kuo, C, Wang, SP, Grayston, JT. Ofloxacin treatment of Cklamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med. 1990;89:722–724.Google Scholar
74. Gentry, LO, Rodriguez-Gomez, G, Zeluff, BJ, Khoshdel, A, Price, M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med. 1989;87:57S–60S.Google Scholar
75. Ketterl, R, Beckurts, T, Stubinger, B, Claudi, B. Antibiotic therapy in the treatment of chronic osteitis under specific consideration of ofloxacin. Drugs. 1987;34(suppl 1)124–130.Google Scholar
76. Wang, F, Gu, XJ, Zhang, MF, Tai, TY. Treatment of typhoid fever with ofloxacin. J Antimicrob Chemother. 1989;23:785–788.CrossRefGoogle ScholarPubMed
77. Liang, RHS, Yung, RWH, Chan, TK, et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990;34:215–218.CrossRefGoogle ScholarPubMed
78. Tack, KJ, Smith, JA. The safety profile of ofloxacin. Am J Med. 1989;87:78S-81S.Google Scholar
79. Kohler, RB, Arkins, N, Tack, KJ. Accidental overdose of intravenous ofloxacin with benign outcome. Antimicrob Agents Chemother. 1991;35:1239–1240.Google Scholar